She is more vulnerable now even with insiders holding 20% than she was during the Woodford years. This is a proven product especially in the recent combination trials. Even if she put together a consortium of investors, and she knows people with billions, and offered $5 per share without the poison pill going into effect she would lose control. MRK could come in with a slightly better offer and any judge would say the poison pill no longer is in effect due to the management’s action of trying to go private without it. I guarantee MRK after outbidding within six months would be selling combination therapy for GBM. They could do it without Advent personnel. NWBO owns the IP and I doubt CRL would turn down MRK to run the facility with old Cognate personnel.
At this price she is very vulnerable. Mostly has herself to blame.
Market Data 
Markets 
AI
